Download to XLS

Document and Entity Information

v2.4.0.6
Document and Entity Information
9 Months Ended
Sep. 30, 2012
Nov. 14, 2012
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2012  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q3  
Entity Registrant Name TARGETED MEDICAL PHARMA, INC.  
Entity Central Index Key 0001420030  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   22,900,761

CONSOLIDATED BALANCE SHEETS

v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
Sep. 30, 2012
Dec. 31, 2011
Current Assets:    
Cash and Cash Equivalents $ 4,210 $ 147,364
Inventory 854,202 495,821
Accounts Receivable 554,053 899,493
Loans Receivable - Employees 19,095 23,360
Prepaid Expenses - Short Term 357,646 241,208
Prepaid Taxes 894,301 792,301
Deferred Tax Asset - Short Term 222,628 300,170
Total Current Assets 2,906,135 2,899,717
Property and Equipment - Net of Accumulated Depreciation 384,217 411,823
Intangible Assets - Net of Accumulated Amortization 2,347,880 2,387,801
Prepaid Expenses - Long Term 53,451 111,259
Deferred Tax Asset - Long Term 5,326,093 3,141,176
Other Assets 46,000 26,000
Total Assets 11,063,776 8,977,776
Liabilities:    
Accounts Payable and Accrued Expenses 6,549,536 5,035,136
Notes Payable-Related Parties: Short-term 5,122,000 1,775,561
Other Amounts due to Related Parties 335,448 602,948
Deferred Tax Liability - Current 69,648 69,648
Derivative Liability 426,625  
Total Current Liabilities 12,167,809 7,483,293
Notes Payable-Related Parties:Long-term (net of $171,452 discount) 363,996  
Deferred Income Taxes 1,002,283 887,050
Total Liabilities 13,534,088 8,370,343
Shareholders' Equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized, no shares issued and outstanding      
Common stock, $0.001 par value; 100,000,000 shares authorized, 22,049,576 and 21,949,576 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively 22,050 21,950
Additional Paid-In Capital 6,648,433 4,684,095
Accumulated Deficit (9,140,795) (4,098,612)
Total Shareholders' Equity (Deficit) (2,470,312) 607,433
Total Liabilities and Shareholders' Equity (Deficit) $ 11,063,776 $ 8,977,776

CONSOLIDATED BALANCE SHEETS (Parenthetical)

v2.4.0.6
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Sep. 30, 2012
Dec. 31, 2011
Notes Payable-Related Parties Long-term, discount $ 171,452  
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued      
Preferred stock, shares outstanding      
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000